Rhabdomyolysis in a prostate cancer patient taking ketoconazole and simvastatin: Case report and review of the literature

Annals of Pharmacotherapy

Volumn 45, Issue 2, 2011, Pages

  Watkins, Jack L ^a   Atkinson, Bradley J ^a   Pagliaro, Lance C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Ketoconazole; Prostate cancer; Rhabdomyolysis; Simvastatin

Indexed keywords

BICALUTAMIDE; BICARBONATE; CREATINE KINASE; CREATININE; ELECTROLYTE; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FUROSEMIDE; KETOCONAZOLE; LEUPRORELIN; LEVOFLOXACIN; LEVOTHYROXINE; MEVINOLIN; MYOGLOBIN; PREDNISONE; SIMVASTATIN; SODIUM CHLORIDE; VERAPAMIL; ANTINEOPLASTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE KIDNEY FAILURE; ADD ON THERAPY; ADULT; AMBULATORY CARE; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLOOD SAMPLING; CANCER RADIOTHERAPY; CASE REPORT; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; HEMATURIA; HEMODIALYSIS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTHYROIDISM; KIDNEY FUNCTION; LABORATORY TEST; MALE; MORBID OBESITY; MUSCLE WEAKNESS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE CANCER; REHYDRATION; RENOGRAPHY; RHABDOMYOLYSIS; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; URINALYSIS; URINARY TRACT INFECTION; URINE CULTURE; ACUTE KIDNEY INJURY; AGED; CHEMICALLY INDUCED; DRUG COMBINATION; DRUG INTERACTION; PROSTATIC NEOPLASMS; RENAL REPLACEMENT THERAPY;

ACUTE KIDNEY INJURY; AGED; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FENOFIBRATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KETOCONAZOLE; MALE; PROSTATIC NEOPLASMS; RENAL DIALYSIS; RHABDOMYOLYSIS; SIMVASTATIN;

EID: 79951867093     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P433     Document Type: Article

References (28)

1. Hsieh A, Ryan C. Novel concepts in androgen receptor blockade. Cancer J 2008;14:11-4. DOI 10.1097/PPO.0b013e318161d13e
2. Van Allen EM, Ryan CJ. Novel secondary hormonal therapy in advanced prostate cancer: an update. Curr Opin Urol 2009;19:315-21. DOI 10.1097/MOU.0b013e328329b73a
3. National cancer institute. 2010. Prostate cancer (PDQ): treatment. www.cancer.gov/cancertopics/pdq/treatment/prostate/HealthProfessional (accessed 2010 Jul 25).
4. Damber JE, Aus G. Prostate cancer. Lancet 2008;371:1710-21. DOI 10.1016/S0140-6736(08)60729-1 (Pubitemid 351671887)
5. Nakabayashi M, Xie W, Regan M, Jackman D, Kantoff P, Oh W. Response to low dose ketoconazole and subsequent dose escalation to highdose ketoconazole in patients with androgen-independent prostate cancer. Cancer 2006;107:975-81. DOI 10.1002/cncr.22085 (Pubitemid 44291146)
6. Harris K, Weinberg V, Bok R, Kakefuda M, Small E. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol 2002;168:542-5. DOI 10.1016/S0022-5347(05) 64675-7 (Pubitemid 34793290)
7. Nobes JP, Langley SE, Laing RW. Metabolic syndrome and prostate cancer: a review. Clin Oncol (R Coll Radiol) 2009;21(3):183-91. DOI 10.1016/j.clon.2008. 11.013
8. Bosch X, Poch E, Grau J. Rhabdomyolysis and acute kidney injury. N Engl J Med 2009;361:62-72. www.nejm.org/doi/full/10.1056/NEJMra0801327#t=article
9. Molden E, Andersson K. Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics. Pharmacotherapy 2007;24:603-7. DOI 10.1592/phco.27.4.603 (Pubitemid 46536242)
10. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97:52C-60C. DOI 10.1016/j.amjcard.2005.12.010
11. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998;64:177-82. http://www.nature.com/clpt/journal/v64/n2/ full/clpt199899a.html (Pubitemid 28423853)
12. Chilab S, Macias E, Garbvie N. A patient with back pain and unusual appearances on bone scintigraphy. Br J Radiol 2004;77:801-2. DOI 10.1259/bjr/77749521 (Pubitemid 39386935)
13. Hod N, Fishman S, Horne T. Detection of rhabdomyolysis associated with compartment syndrome by bone scintigraphy. Clin Nucl Med 2002;27:885-6.
14. Fenneteau F, Poulin P, Nekka F. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A4 substrates. J Pharm Sci 2010;99:486-514. DOI 10.1002/jps.21802
15. Package insert. Vytorin (simvastatin/ezetimibe). North Wales, PA: Merck/Schering-Plough Pharmaceuticals. May 2010. http://www.msppharma.com/ msppharma/documents/vytorin-pi.pdf.
16. Package insert. Zocor (simvastatin). Whitehouse Station, NJ: Merck and Company, Inc, May 2010. http://www.merck.com/product/usa/pi-circulars/z/zocor/ zocor-pi.pdf.
17. Unal A, Torun E, Sipahioglu MH, et al. Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients. Intern Med 2008;47:1017-9. DOI 10.2169/internalmedicine.47.0939
18. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45. DOI 10.1038/clpt.1981.154 (Pubitemid 12149145)
19. Horn JR, Hansten PD, Chan L-N. Proposal for new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41:674-80. DOI 10.1345/aph.1H423 (Pubitemid 46625492)
20. Stein C, Goel S, Ghavamian R. Hepatitis and rhabdomyolysis in a patient with hormone refractory prostate cancer on ketoconazole and concurrent lovastatin therapy. Invest New Drugs 2007;25:277-8. DOI 10.1007/s10637-006-9032- 52 (Pubitemid 46774705)
21. Itakura H, Vaughn D, Haller D, O'Dwyer P. Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer. J Urol 2003;169:613. DOI 10.1016/S0022-5347(05)63967-5 (Pubitemid 36132996)
22. Gilad R, Lampl Y. Rhabdomyolysis induced by simvastatin and ketoconazole treatment. Clin Neuropharmacol 1999;22:295-7. (Pubitemid 29506401)
23. Akram K, Rao S, Parker M. A lesson for everyone in drug-drug interactions (letter). Int J Cardiol 2007;118:e19-20. DOI 10.1016/j.ijcard.2006.11.235
24. Madan R, Lieberman R, Gulley J, Dahut W, Arlen P. Significant prostate specific antigen response to low-dose ketoconazole in a patient with non-metastatic androgen-independent prostate cancer and a review of the literature. Am J Ther 2007;14:310-3. DOI 10.1097/01.pap.0000249955.77460.f4 (Pubitemid 46791571)
25. Small EJ, Halabi S, Dawson N, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004;22:1025-33. DOI 10.1200/JCP.2004.06.037 (Pubitemid 41095034)
26. Saylor P, Smith M. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2009;181:1998-2008. DOI 10.1016/j.juro.2009. 01.047
27. Ang J, Olmos D, de Bono J. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer 2009;100:671-5. DOI 10.1038/sj.bjc.6604904
28. Hu Q, Negri M, Jahn-Hoffman K, et al. Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17) - part II: core rigidification and influence of substituents at the methylene bridge. Bioorg Med Chem 2008 Aug 15;16:7715-27. DOI 10.1016/j.bmc.2008.07.011